223 related articles for article (PubMed ID: 24564812)
1. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
Patel RA; Walberg MP; Tong E; Tan F; Rummel AE; Woelfel JA; Carr-Lopez SM; Galal SM
J Manag Care Spec Pharm; 2014 Mar; 20(3):283-90. PubMed ID: 24564812
[TBL] [Abstract][Full Text] [Related]
2. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
3. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
4. Encouraging generic use can yield significant savings.
Zimmerman C
Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
[TBL] [Abstract][Full Text] [Related]
5. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
Hoadley JF; Merrell K; Hargrave E; Summer L
Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
[TBL] [Abstract][Full Text] [Related]
6. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
[TBL] [Abstract][Full Text] [Related]
7. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
Sacks CA; Lee CC; Kesselheim AS; Avorn J
JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
[TBL] [Abstract][Full Text] [Related]
8. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing.
Bazalo G; Weiss RC
Consult Pharm; 2012 Apr; 27(4):269-73. PubMed ID: 22498986
[TBL] [Abstract][Full Text] [Related]
9. Private expenditures on brand name prescription drugs after generic entry.
Balaban DY; Dhalla IA; Law MR; Bell CM
Appl Health Econ Health Policy; 2013 Oct; 11(5):523-9. PubMed ID: 23979876
[TBL] [Abstract][Full Text] [Related]
10. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
Carroll NV
J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
[TBL] [Abstract][Full Text] [Related]
11. Generic-only drug coverage in the Medicare Part D gap and effect on medication cost-cutting behaviors for patients with diabetes mellitus: the translating research into action for diabetes study.
Duru OK; Mangione CM; Hsu J; Steers WN; Quiter E; Turk N; Ettner SL; Schmittdiel JA; Tseng CW
J Am Geriatr Soc; 2010 May; 58(5):822-8. PubMed ID: 20406312
[TBL] [Abstract][Full Text] [Related]
12. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017.
Bartlett VL; Liu P; Dhruva SS; Shah ND; Bollinger KE; Ross JS
J Manag Care Spec Pharm; 2020 Apr; 26(4):562-567. PubMed ID: 32223594
[TBL] [Abstract][Full Text] [Related]
13. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.
Sumarsono A; Lalani HS; Vaduganathan M; Navar AM; Fonarow GC; Das SR; Pandey A
JAMA Cardiol; 2021 Jan; 6(1):92-96. PubMed ID: 32902560
[TBL] [Abstract][Full Text] [Related]
14. Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available.
Dusetzina SB; Cubanski J; Nshuti L; True S; Hoadley J; Roberts D; Neuman T
Health Aff (Millwood); 2020 Aug; 39(8):1326-1333. PubMed ID: 32744944
[TBL] [Abstract][Full Text] [Related]
15. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
[TBL] [Abstract][Full Text] [Related]
16. Cost minimization of medicare part D prescription drug plan expenditures.
Patel RA; Lipton HL; Cutler TW; Smith AR; Tsunoda SM; Stebbins MR
Am J Manag Care; 2009 Aug; 15(8):545-53. PubMed ID: 19670958
[TBL] [Abstract][Full Text] [Related]
17. Potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) study.
Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF; Fu J; Simien L; Tseng CW
J Gen Intern Med; 2014 Jan; 29(1):230-6. PubMed ID: 23975059
[TBL] [Abstract][Full Text] [Related]
18. Five-year impact of Medicare Part D coverage gap reform on drug expenditures and utilization.
Park J; Look KA
Health Serv Res; 2022 Feb; 57(1):56-65. PubMed ID: 33870486
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
20. How does drug coverage vary by insurance type? Analysis of drug formularies in the United States.
Régnier SA
Am J Manag Care; 2014 Apr; 20(4):322-31. PubMed ID: 24884863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]